The first Head of State multi-mission Global 7500 aircraft delivered to armasuisse by Bombardier Defense was unveiled to the public on January 29th, in Bern, Switzerland Military and government operators appreciate the Global 7500 aircraft’s capabilities that optimize performance, efficiency and safety to support both head-of-state transportation and emergency evacuation missions Bombardier Defense has an active fleet of Global and Challenger aircraft in service that are tailored to ensure maximized efficiency for government transport, by gearing the cabin for productivity and safetyBERN, Switzerland, Jan. 29, 2025 (GLOBE NEWSWIRE) — Bombardier Defense today celebrated the first public unveiling of armasuisse’s newly-delivered Global 7500 multi-mission aircraft. The platform will be equipped for government and military personnel...

CAMBRIDGE, Massachusetts, Jan. 29, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 1:30 p.m. ET in New York, NY. A live webcast of the fireside chat may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com, and will be available for at least 30 days following the event. About ProMIS Neurosciences...

GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference. Details are as follows:  Conference: Guggenheim SMID Cap Biotech Conference       Date/Time: Wednesday, February 5, 2025, at 9:30 a.m. EST     The session will be webcast and can be accessed by visiting the Events section of the Altimmune website. About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com. Follow...

Three Consecutive Years Without Lost-time Accidents VANCOUVER, British Columbia, Jan. 29, 2025 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF) (“Amerigo” or the “Company”) is pleased to announce that Minera Valle Central (“MVC”), the Company’s 100% owned operation located near Rancagua, Chile, has reached a significant safety milestone, marked by three consecutive years without lost-time accidents. During these three years, a total of 1,823,782 man-hours were lodged by MVC’s employees. “This new safety record reached by the MVC team is significant as it demonstrates the safety mindset and the effectiveness of the safety practices, training programs and tools in place at our operation. Our maxims that safety supersedes all production goals and that all workers should return home unharmed each day have clearly...

SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 1:00 p.m. E.T. A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About Apogee Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD, EoE and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of...

DUNMORE, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) — Fidelity D & D Bancorp, Inc. (NASDAQ: FDBC) and its banking subsidiary, The Fidelity Deposit and Discount Bank (“the Company”), announced its unaudited, consolidated financial results for the three and twelve month periods ended December 31, 2024. Unaudited Financial Information Net income recorded for the year ended December 31, 2024 was $20.8 million, or $3.60 diluted earnings per share, compared to $18.2 million, or $3.19 diluted earnings per share, for the year ended December 31, 2023. The $2.6 million, or 14% increase in net income resulted primarily from the $7.6 million increase in non-interest income for 2024 compared to 2023. During 2023, the Company sold available-for-sale securities resulting in a $6.5 million loss, $5.1 million net of tax, which was the...

PETACH TIKVA, Israel, Jan. 29, 2025 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 12, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast. Conference Call Dial-In & Webcast Information:  Date:  Wednesday,...

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) — Amwell® (NYSE: AMWL), a leader in digital care, will report fourth quarter 2024 operating results after stock market trading hours on Wednesday, Feb. 12. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company’s operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company’s website. A webcast replay of the call will be available at investors.amwell.com for approximately 90 days. About Amwell  Amwell is a leading hybrid care, delivery enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators...

HOUSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) — U.S. Energy Corp. (NASDAQ: USEG, “U.S. Energy” or the “Company”) today announced that its Board of Directors has authorized the extension of the previously announced share repurchase program under which the Company may purchase up to $5.0 million of its outstanding shares of common stock in the open market, in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Securities Exchange Act of 1934, as amended. The repurchase program was originally approved in April 2023 and extended in March 2024, and was to expire on June 30, 2025. The expiration date has now been extended until June 30, 2026. A total of up to approximately $3.8 million remains available under the repurchase program for future repurchases. The Company’s decision to repurchase its shares,...

U.S. Consumer net sales increased 11 percent driven by strong fall lawn and garden campaign and retailer support for 2025 spring season Consumer POS, which represents less than 10 percent of the full-year, was up 12 percent in dollars and 13 percent in units GAAP gross margin rate of 22.7 percent improved 750 bps; Non-GAAP adjusted gross margin rate of 24.0 percent improved 1,030 bps Non-GAAP Adjusted EBITDA of $4 million reflected $30 million improvement GAAP loss of $1.21 per share and non-GAAP adjusted loss of $0.89 per share improved $0.21 and $0.56 per share, respectively Company reaffirms full-year sales, adjusted gross margin and adjusted EBITDA guidance; lowers interest expense guidanceMARYSVILLE, Ohio, Jan. 29, 2025 (GLOBE NEWSWIRE) — The Scotts Miracle-Gro Company (NYSE: SMG), the world’s largest marketer of branded...